3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
3
Terminated
2
Recruiting
2
Not yet recruiting
1
Enrolling by invitation
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
5
Genitourinary
2
Classical hematology
2
Myeloid
1
Gynecologic
1
Breast
1
Conditions
Venous Thromboembolism
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Hemorrhage
1
Interventions
Cyclophosphamide
11
fludarabine phosphate
8
fludarabine
8
apixaban
8
Mycophenolic Acid
6
Melphalan
6
Busulfan
6
Whole-Body Irradiation
4
Tacrolimus
4
Rivaroxaban
4
Filgrastim
4
Biopsy
4
thymoglobulin
3
X-Rays
3
Specimen Handling
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Hematopoietic Stem Cell Transplantation
3
Granulocyte Colony-Stimulating Factor
3
Enoxaparin
3
Bone Marrow Transplantation
3
Azacitidine
3
venetoclax
2
pegylated granulocyte colony-stimulating factor
2
olaparib
2
Tretinoin
2
Stem Cell Transplantation
2
Mesna
2
Injections
2
Heparin, Low-Molecular-Weight
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Aspirin
×
Classical hematology
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled